|
Gene: PCDH11X |
Gene summary for PCDH11X |
Gene summary. |
Gene information | Species | Human | Gene symbol | PCDH11X | Gene ID | 27328 |
Gene name | protocadherin 11 X-linked | |
Gene Alias | PCDH-X | |
Cytomap | Xq21.31 | |
Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | Q9BZA7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
27328 | PCDH11X | p6 | Human | Liver | Cyst | 9.43e-17 | 7.23e-01 | -0.0218 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PCDH11X | SNV | Missense_Mutation | c.3175N>C | p.Glu1059Gln | p.E1059Q | Q9BZA7 | protein_coding | tolerated(0.29) | possibly_damaging(0.731) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PCDH11X | SNV | Missense_Mutation | c.3847N>A | p.Val1283Met | p.V1283M | Q9BZA7 | protein_coding | tolerated_low_confidence(0.16) | benign(0.005) | TCGA-D8-A13Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
PCDH11X | SNV | Missense_Mutation | c.2906A>T | p.Asp969Val | p.D969V | Q9BZA7 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PCDH11X | SNV | Missense_Mutation | c.1955C>T | p.Ser652Leu | p.S652L | Q9BZA7 | protein_coding | deleterious(0) | possibly_damaging(0.602) | TCGA-OL-A5DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PCDH11X | insertion | In_Frame_Ins | novel | c.3318_3319insGTAAACAAA | p.Gly1106_Asp1107insValAsnLys | p.G1106_D1107insVNK | Q9BZA7 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
PCDH11X | insertion | In_Frame_Ins | novel | c.1496_1497insCACTCAACACCAAAATTGCTCTCA | p.Ala499_Lys500insThrGlnHisGlnAsnCysSerHis | p.A499_K500insTQHQNCSH | Q9BZA7 | protein_coding | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PCDH11X | SNV | Missense_Mutation | c.1676N>A | p.Ser559Asn | p.S559N | Q9BZA7 | protein_coding | tolerated(0.37) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PCDH11X | SNV | Missense_Mutation | novel | c.2132N>C | p.Val711Ala | p.V711A | Q9BZA7 | protein_coding | deleterious(0) | benign(0.101) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PCDH11X | SNV | Missense_Mutation | novel | c.3416N>A | p.Cys1139Tyr | p.C1139Y | Q9BZA7 | protein_coding | deleterious(0) | benign(0.306) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PCDH11X | SNV | Missense_Mutation | novel | c.3644N>G | p.Gln1215Arg | p.Q1215R | Q9BZA7 | protein_coding | deleterious_low_confidence(0.01) | benign(0.018) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |